CD274 and non-small cell lung carcinoma: The expert consensus on immunosuppressive therapy for NSCLC in China (2019) recommends nivolumab monotherapy as the preferred second-line treatment for advanced NSCLC with no EGFR mutations or ALK translocations, regardless of PD-L1 expression (30).